207.59
+1.39%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ICON
Its shares trade under the ticker ICLR. It has been listed since 15 May 1998. In the fiscal year to 31 December 2025, it reported revenue of $8.25bn and net income of $229.3m. At that date it held total assets of $16.27bn and shareholders' equity of $9.19bn.
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The company is headquartered in Dublin, Dublin. The firm is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. Its services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. The firm's information systems offerings include ICONIK, Firecrest, ADDPLAN, AptivAdvantage and Aptiv Insite. The company conducts various laboratory tests on the patient's blood, urine and other bodily fluids at appropriate intervals during the trial. The firm offers clinical development services, including investigator recruitment, patient registries, outcomes research, clinical data management, immunoassay development and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 15 May 1998
- Employees
- 40,100
- Website
- iconplc.com ↗
- Head office
- SOUTH COUNTY BUSINESS PARK, DUBLIN 18, L2, 00000
- Classification
- Services-Commercial Physical & Biological Research
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Ciaran MurrayNon-Executive Independent Chairman of the Board, since 2005$658,000
- Mr. Barry BalfeChief Executive Officer, Chief Operating Officer
- Mr. Nigel ClerkinChief Financial Officer$247,000
- Mr. Diarmaid CunninghamChief Administrative Officer, General Counsel, Company Secretary
- Mr. Ronan MurphyLead Independent Director$387,000
- Dr. Stephen CutlerNon-Executive Director, since 2014$4.5m
- Dr. John ClimaxIndependent Director, since 1990$311,000
- Dr. Linda GraisIndependent Director$332,000
- Mr. Eugene MccagueIndependent Director$343,000
- Ms. Julie O'NeillIndependent Director$336,000
- Ms. Anne WhitakerIndependent Director$50,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 59
- Environment
- 54
- Social
- 83
- Governance
- 40
- Direct emissions (scope 1)
- 2,503 t
- Energy emissions (scope 2)
- 13,663 t
- Value chain emissions (scope 3)
- 25,353 t
- Women in the workforce
- 71.90251%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ICON PLC has established a strong global presence in the pharmaceutical and biotechnology industry, gaining a reputation as a trusted partner in clinical research and development.
- The company offers a wide range of services including clinical trial management, data management, laboratory services, and consulting, enabling clients to streamline their drug development processes.
- ICON PLC has a strong focus on technological advancements, leveraging innovative tools and technologies to improve the efficiency and accuracy of clinical trials and data analysis.
Weaknesses
- ICON PLC's revenue is heavily reliant on a few key clients, which poses a risk to the company's financial stability in case of potential loss or reduced business from these clients.
- The company's service offerings are primarily focused on clinical research and development, leaving it susceptible to changes in the pharmaceutical industry and potential shifts in client demands.
Opportunities
- With the increasing global healthcare expenditure and demand for innovative treatments, ICON PLC can capitalize on the growing market by expanding its services and targeting emerging markets.
- Continuous advancements in technology, such as the use of artificial intelligence and big data analytics, present opportunities for ICON PLC to enhance its service offerings, improve operational efficiency, and deliver more accurate insights to its clients.
Threats
- The pharmaceutical industry is subject to strict regulatory requirements that can impact the speed and cost of drug development. Non-compliance or changes in regulations pose threats to ICON PLC's operations and profitability.
- The industry is highly competitive, with numerous players offering similar services. ICON PLC faces the risk of losing market share to competitors who may offer more cost-effective or innovative solutions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.